Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 2 Cumulative distribution plot of the incremental cost-effectiveness ratio for paclitaxel-eluting stent compared with bare-metal stent based on bootstrap analysis of the primary TAXUS-IV trial results among the overall study population (A) and the subgroup assigned to clinical follow-up alone (B). As indicated by the arrow, 86% of the resulting cost-effectiveness ratios were <$10,000 per target vessel revascularization event avoided for the overall population, and 90% were less than this threshold for the clinical follow-up cohort.
|
